Skip to main content
. 2021 Sep;9(18):1447. doi: 10.21037/atm-21-3928

Figure 5.

Figure 5

TIM3 blockade restores the function of tumor-infiltrating CD8+ T cells in vivo. (A) Kaplan-Meier survival curve showing significantly improved survival in mice treated with anti-mouse TIM-3 antibody compared with isotype control (P=0.0016). Of note, all mice in the vehicle group died by week 6. (B,C) CyTOF (viSNE plot) analysis of live CD45+ cells from representative tumors from mice treated with isotype control (B) or anti-mouse TIM-3 antibody (C). (D) Quantification of tumor-infiltrating cells shown in (B,C) (n=5 each). (E) Expression of cytokines in CD8+ T cells isolated from representative tumors from mice treated with isotype control or anti-mouse TIM-3 antibody pre- and post-activation with PMA and ionomycin. Data are mean ± SD, n=5. For (D,E), *, P<0.05; **, P<0.01; ****, P<0.0001, ns, not significant (P>0.05)—one-way ANOVA with Tukey’s post hoc test. TIM3, T cell immunoglobulin and mucin-domain containing 3; CyTOF, mass cytometry by time-of-flight; OS, osteosarcoma; PMA, phorbol 12-myristate 13-acetate.